Jump to sections

Procalcitonin (PCT), Sepsis and Smarter Antibiotic Use: Why This Biomarker Saves Lives and Reduces Costs

19.5 Minutes to read
Written by Axonlab
Microbiology

Evidence-Based Infection Diagnostics in the Era of Antibiotic Resistance

The rapid diagnosis and treatment of bacterial infections remain among the greatest challenges in modern medicine. Particularly in cases of sepsis, every hour can make a difference in patient outcomes. At the same time, diagnostic uncertainty often leads to the broad use of antibiotics before microbiological test results become available.

The consequences are well known: increasing antibiotic resistance, adverse drug reactions, Clostridioides difficile infections, prolonged hospital stays, and rising healthcare costs. Biomarkers that enable improved differentiation between bacterial and non-bacterial inflammation are therefore becoming increasingly important.

Among these biomarkers, procalcitonin (PCT) has established itself over the past two decades as one of the most extensively studied and scientifically validated markers. Today, PCT is incorporated into numerous national and international clinical guidelines and is considered a key component of modern antibiotic stewardship programs. ¹ ⁷

What is Procalcitonin?

Procalcitonin is the precursor of the hormone calcitonin and is produced only in very small quantities under physiological conditions. During systemic bacterial infections, however, pronounced extrathyroidal expression occurs, resulting in a rapid increase in serum concentrations.

As early as 1993, Assicot et al. described the association between elevated PCT levels and severe bacterial infections. Subsequent studies demonstrated that PCT not only correlates with the presence of bacterial infection but often also reflects disease severity. ² ³

Unlike many other inflammatory markers, PCT remains low in many viral infections. This characteristic makes it particularly useful for supporting therapeutic decision-making in daily clinical practice. ³

Limitations of Interpretation

Despite its strong diagnostic value, procalcitonin is not a perfect biomarker. Elevated PCT levels may also occur in certain non-infectious conditions, such as major surgery, severe trauma, burns, cardiogenic shock, or pronounced inflammatory autoimmune diseases. Conversely, PCT levels may still be low during the early phase of localized bacterial infections. Therefore, PCT results should always be interpreted within the broader clinical context and never in isolation. ² ³ ⁶

PCT compared with CRP and IL-6

No single biomarker can replace clinical assessment. However, available biomarkers differ significantly in their diagnostic performance.

Medcaptain data clearly illustrate the different kinetics of IL-6, PCT, and CRP during sepsis. PCT stands out through its unique combination of diagnostic specificity and clinical practicality.

Figure 1: Kinetics of Key Inflammatory Biomarkers in Sepsis

Characteristic	IL-6	PCT	CRP
Rise after infection	1-2 hours	6-12 hours	12-24 hours
Half-life	approx. 1 hour	approx. 24 hours	approx. 19-20 hours
Specificity for bacterial infection	low-moderate	high	low
Suitability for sepsis diagnosis	sehr gut	very good	supportive
Suitability for antibiotic stewardship	limited	very good	limited
Suitability for therapy monitoring	limited	very good	good

Table 1: Comparison of Key Inflammatory Biomarkers

PCT and the diagnosis of sepsis

Despite significant advances in medical care, sepsis remains one of the leading causes of death in acute care hospitals. Clinical symptoms are often non-specific and overlap with numerous non-infectious conditions.

Blood cultures remain the diagnostic gold standard, but definitive results often require several days. Meanwhile, survival rates decrease significantly when treatment initiation is delayed.

The Medcaptain documentation also illustrates the relationship between PCT concentration and the severity of bacterial infections.

Figure 2: Relationship between PCT and Severity of Infection

As infection severity increases, PCT concentrations typically rise, progressing from localized bacterial infections to sepsis and septic shock. Consequently, PCT is now used not only to support diagnosis but also for risk stratification and monitoring treatment response. ² ³

PCT and Antibiotic Stewardship: The strongest Evidence

The greatest clinical value of PCT today lies no longer primarily in diagnosis, but in guiding antibiotic therapy.

The landmark PRORATA study was the first to demonstrate that PCT-guided algorithms can significantly reduce antibiotic exposure in intensive care units. After 28 days, patients in the PCT group had approximately 2.7 more antibiotic-free days than patients receiving standard care, without any increase in mortality or treatment failure. ¹⁰

The randomized study by de Jong et al. confirmed these findings impressively. The duration of antibiotic therapy was reduced from 7.0 to 5.0 days, while 28-day mortality was not increased. ¹¹

Further evidence was provided by:

ProHOSP Trial (Schuetz et al.) ¹²
Wirz et al. Individual Patient Meta-Analysis¹³
NeoPInS Trial bei Neugeborenen¹⁴
Several international meta-analyses ¹⁵

The central message across these studies is remarkably consistent:

Less antibiotic use, without higher mortality, increased treatment failure, or longer hospital stays.

New Evidence: Does the Benefit Extend Beyond Antibiotic Reduction?

A particularly noteworthy study by Kyriazopoulou et al. demonstrated that PCT-guided antibiotic de-escalation in sepsis patients not only reduces antibiotic use but may also decrease long-term infection-associated complications. ¹⁶

These findings suggest that PCT may be far more than a tool for reducing antibiotic consumption. Rather, it may help improve long-term clinical outcomes in patients with sepsis.

Evidence at a glance

Studie	Klinisches Setting	Quantitativer Effekt
PRORATA Bouadma et al.	Intensive Care Medicine	+2,7 antibiotic-free days within 28 days ¹⁰
ProHOSP Schuetz et al.	Lower Respiratory Tract Infections	Approximately 35 % reduction in antibiotic exposure ¹²
de Jong et al.	Intensive Care Unit	Reduction in antibiotic therapy duration from 7 to 5 days ¹¹
Wirz et al.	Individual Patient Data Meta-analysis	Significant reduction in antibiotic exposure by approximately 1 day in ICU patients, no increase in treatment failure, with additional indication of improved survival across several analyzed patient groups. ¹³
NeoPInS Stocker et al.	Neonatology	Reduction in therapy duration by approximately 22 hours ¹⁴
Kyriazopoulou et al.	Sepsis	Fewer infection-associated long-term complications¹⁶

Table 2: Selection of Key Clinical Studies on Procalcitonin

These studies form the foundation of current guideline recommendations and explain why PCT is now considered one of the most thoroughly validated biomarkers in the field of Antibiotic Stewardship. ⁴ ⁶ ¹⁵

International Gudelines Support the use of PCT

The scientific evidence has been incorporated into numerous clinical guidelines, including:

Surviving Sepsis Campaign 2021⁴
ATS/IDSA Guidelines for Community-Acquired Pneumonia ¹⁷
ERS/ESICM/ESCMID/ALAT Guidelines for severe Pneumonia ¹⁸
Pediatric recommendations for febrile infants ¹⁹
Neonatal recommendations for early sepsis diagnostics ¹⁴

In addition, the World Health Organization (WHO) includes Procalcitonin on its Model List of Essential In Vitro Diagnostics. ⁷

Economic Benefits: Why PCT is also attractive for hospitals

Beyond its clinical advantages, the health-economic perspective is highly relevant. The cost of a PCT test is often considered in isolation. However, a broader evaluation of the entire patient pathway is far more meaningful.

Studies have shown that PCT-guided therapy can lead to:

shorter antibiotic treatment durations
lower medication costs
fewer antibiotic-associated adverse events
reduced development of antimicrobial resistance
shorter hospital stays
lower readmission rates ²⁰ ²¹

Several health-economic analyses have concluded that the cost of PCT testing is often more than offset by the resulting downstream savings. ^{20 21}

For Antibiotic Stewardship programs, PCT is therefore not only clinically valuable but frequently economically advantageous as well.

From Evidence to Clinical Practice: The Medcaptain Immu F6

The evidence supporting PCT is compelling. The crucial question, however, is:

How can these insights be efficiently translated into everyday clinical practice?

This requires powerful diagnostic platforms capable of delivering rapid and reliable results.

The Medcaptain Immu F6 is a compact chemiluminescence immunoassay (CLIA) system specifically designed for acute care settings, emergency departments, intensive care units, satellite laboratories, and smaller diagnostic laboratories.

Key Features

Fully automated chemiluminescence technology (acridinium ester)
whole blood, serum and plasma analysis
First results available in approximately 13.5 minutes
Random access und STAT functionality
Single-use cartridge system to minimize cross-contamination, particularly noteworthy is the platform strategy behind the system

More than PCT:A Platform for Modern Sepsis Management

The Immu F6 enables the measurement of multiple complementary inflammatory biomarkers on a single platform.

Available markers include:

PCT (Procalcitonin)
IL-6
CRP / hs-CRP
SAA (Serum Amyloid A)

The combination of these markers reflects the current understanding of a multimodal approach to sepsis diagnostics.

Biomarker	Primary Function
IL-6	Early warning marker
PCT	Detection of bacterial infection and guidance of antibiotic therapy
CRP	Monitoring of inflammatory response
SAA	Acute inflammatory response

Medcaptain documentation specifically recommends the combined use of IL-6 and PCT for the management of sepsis patients.

In addition, the Immu F6 menu includes more than 50 parameters spanning cardiology, coagulation, inflammation, endocrinology, and other specialized clinical areas. This allows the same platform to be used for a wide range of diagnostic applications.

Conclusion

Procalcitonin has evolved from a diagnostic biomarker into one of the most important tools in modern Antibiotic Stewardship.

Evidence from studies such as PRORATA, ProHOSP, de Jong et al., NeoPInS, and Kyriazopoulou et al. consistently demonstrates:

reduced antibiotic use
lower healthcare costs
maintained or improved pationt safety
potential improvement of long-term clinical outcomes ¹⁰–¹⁶

At the same time, practical experience shows that the value of any biomarker can only be realized when results are available quickly and reliably. Platforms such as the Medcaptain Immu F6 enable the implementation of these evidence-based concepts in routine clinical practice, while combining PCT with other relevant biomarkers such as IL-6, CRP, and SAA on a compact chemiluminescence platform.

For healthcare institutions seeking to strengthen Antibiotic Stewardship, limit antimicrobial resistance, and use resources more efficiently, Procalcitonin remains one of the most clinically and economically valuable biomarkers in modern infectious disease management.

Literature

1. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–518.

2. Becker KL, Nylén ES, White JC, Müller B, Snider RH. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection and sepsis. J Clin Endocrinol Metab. 2004;89(4):1512–1525.

3. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Medicine. 2011; 9:107.

4. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Medicine. 2021; 47:1181–1247.

5. Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign Guidelines 2021. Critical Care Medicine. 2021;49(11): e1063–e1143.

6. Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an expert consensus. Clin Chem Lab Med. 2019;57(9):1308–1318.

7. WHO. Model List of Essential In Vitro Diagnostics. World Health Organization. Aktuelle Ausgabe.

8. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812.

9. Hoeboer SH, van der Geest PJ, Nieboer D, Groeneveld ABJ. The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis. Clin Microbiol Infect. 2015 ;21(5):474–481.

10. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA Trial). Lancet. 2010 ;375 (9713) :463–474.

11. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients. Lancet Infect Dis. 2016 ;16(7):819–827.

12. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: ProHOSP Trial. JAMA. 2009;302(10):1059–1066.

13. Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in ICU patients. Critical Care. 2018; 22:191.

14. Stocker M, van Herk W, El Helou S, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonatal early-onset sepsis (NeoPInS). Lancet. 2017;390(10097):871–881.

15. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: individual patient data meta-analysis. Lancet Infect Dis. 2018;18(1):95–107.

16. Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to Reduce Long-Term Infection-Associated Adverse Events in Sepsis. A Randomized Trial. Am J Respir Crit Care Med. 2021;203(2):202–210.

17. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official ATS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(7):e45–e67.

18. Torres A, Cilloniz C, Niederman MS, et al. International ERS/ESICM/ESCMID/ALAT Guidelines for the Management of Severe Community-Acquired Pneumonia. Eur Respir J. 2023;61(4):2200735.

19. Pantell RH, Roberts KB, Adams WG, et al. Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old. Pediatrics. 2021;148(2):e2021052228.

20. Kip MMS, Kusters R, IJzerman MJ, Steuten LMG. A PCT-guided antibiotic treatment strategy in intensive care patients: cost-effectiveness analysis. Applied Health Economics and Health Policy. 2015;13:527–536.

21. Broyles MR. Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Costs. Am J Health Syst Pharm. 2017;74(13):1010–1018.